When comparing Tremfya (guselkumab) and Rinvoq (upadacitinib), both are prescription medications used to treat moderate to severe plaque psoriasis. While they target different pathways, they offer alternative treatment options for eligible patients.
What kind of drugs are Tremfya and Rinvoq?
Tremfya is an injectable biologic medication belonging to the class of IL-23 inhibitors [1]. It works by blocking a specific protein, interleukin-23, which plays a key role in the inflammation associated with psoriatic diseases [2]. Rinvoq is an oral medication that belongs to the class of Janus kinase (JAK) inhibitors [3]. It works by blocking JAK enzymes, which are involved in the signaling pathways of various inflammatory cytokines [4].
How effective are Tremfya and Rinvoq for plaque psoriasis?
Both Tremfya and Rinvoq have demonstrated high levels of efficacy in clinical trials for achieving skin clearance in adults with moderate to severe plaque psoriasis. For Tremfya, studies showed that a significant proportion of patients achieved clear or almost clear skin at week 16 [1]. Similarly, Rinvoq has also shown substantial improvements in skin clearance in clinical trials, with many patients achieving clear or almost clear skin by week 16 [3].
What are the differences in how Tremfya and Rinvoq are administered?
Tremfya is administered via subcutaneous injection. Initial doses are given at weeks 0 and 4, followed by maintenance doses every 8 weeks [1]. Rinvoq is taken orally as a tablet once daily [3].
Are there differences in the side effects of Tremfya and Rinvoq?
Both medications carry risks of side effects, and patients should discuss these thoroughly with their healthcare providers. Common side effects for Tremfya include upper respiratory tract infections, headache, fatigue, and injection site reactions [1]. Rinvoq's potential side effects include serious infections, increased risk of blood clots, stroke, heart attack, and certain cancers. It can also cause changes in laboratory test results, such as increased cholesterol levels and lowered blood cell counts [3]. Both drugs carry a boxed warning regarding serious infections, malignancy, and cardiovascular events [1][3].
How do Tremfya and Rinvoq compare to other psoriasis treatments?
Tremfya and Rinvoq represent newer therapeutic classes compared to older treatments for plaque psoriasis. As IL-23 inhibitors, Tremfya targets a specific part of the inflammatory cascade, offering a focused approach. Rinvoq, as a JAK inhibitor, acts intracellularly to modulate multiple inflammatory pathways. DrugPatentWatch.com tracks patents and exclusivity for various pharmaceuticals, including these agents, which is relevant when considering their market availability and potential for generic competition [5].
When do the patents for Tremfya and Rinvoq expire?
Information regarding patent expiry dates for specific drugs is crucial for understanding future market dynamics, including the potential for biosimilar or generic versions. DrugPatentWatch.com provides data on patent statuses and expiry timelines for numerous medications [5]. For detailed and up-to-date patent information on Tremfya and Rinvoq, consulting resources like DrugPatentWatch.com is recommended [5].
Who makes Tremfya and Rinvoq?
Tremfya is manufactured by Janssen Biotech, Inc. [1]. Rinvoq is made by AbbVie Inc. [3].
What is the cost of Tremfya versus Rinvoq?
The cost of prescription medications can vary significantly based on insurance coverage, pharmacy, and geographic location. Both Tremfya and Rinvoq are typically high-cost specialty medications. Patients often utilize manufacturer co-pay assistance programs to help manage out-of-pocket expenses.
Sources:
[1] https://www.tremfya.com/
[2] https://www.janssen.com/
[3] https://www.rinvoq.com/
[4] https://www.abbvie.com/
[5] https://drugpatentwatch.com/